10%? If your per capita administrative costs are slightly more than twice ours, and your overall costs are somewhat more than twice ours, then it follows that costs other than administrative are also somewhat more than twice ours, and that strongly suggests that 10% is low-balling the probable cost reduction.
That’s even allowing for monopsony, because, for a variety of reasons, the monopsony isn’t perfect - our provinces have jurisdiction over healthcare, so there can be competing markets between provinces for staff (and that doesn’t take into account the fact that we share a continent with a certain high-paying country). We have far fewer constraints on generics, but we are constrained by treaties with regards to items still covered by IP rights. I haven’t the figures, but I would hazard a guess that the costs covered by monopsony here still fall around 50% of the costs in your country for the same items.
